Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia

Sameer A. Parikh, Michael J. Keating, Susan O'Brien, Xuemei Wang, Alessandra Ferrajoli, Stefan Faderl, Jan Burger, Charles Koller, Zeev Estrov, Xavier Badoux, Susan Lerner, William G. Wierda

Research output: Contribution to journal › Article › peer-review

71 Scopus citations

Fingerprint

Dive into the research topics of 'Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds